Under the terms of the amendment and consent agreement, certain provisions of Indevus’ license, commercialization and supply agreement, originally with Odyssey Pharmaceuticals, a subsidiary of Pliva, have been
The drug candidates are small molecule inhibitors of the hepatitis C virus (HCV) NS3/4 protease. These molecules, which have been shown previously to be highly potent, metabolically stable
These restructuring plans, which would include the loss of 63 jobs including the company’s entire dental sales force, follow the FDA approval of generic version of Periostat (doxycycline
This study adds to the established data on Toprol-XL (metoprolol succinate) in the treatment of hypertension in adults. Hypertension affects one in three adults and approximately one in
Following treatment with Introgen’s experimental cancer vaccine, 67% of the evaluable patients in the study had objective responses (greater than 50% tumor reduction) to subsequent chemotherapy. Historically, the
Xcyte said it will shift further clinical development of its lead product, Xcellerated T Cells, to focus on treating HIV. The company intends to submit an investigational new
As well as having shown potential in the treatment of phenylketonuria (PKU), there is preliminary clinical evidence that suggests that the active ingredient in Phenoptin (sapropterin hydrochloride), a
The new tool is designed to provide access to all data made available by the research-based pharmaceutical industry on clinical trial registries and databases around the world. “Disclosure
In the trial, a Taxotere (docetaxel) injection concentrate-based chemotherapy regimen (Taxotere, cisplatin and 5-FU) had significantly improved overall survival rates compared to patients who received a standard treatment
Results from a double-blind phase III study of more than 300 gastrointestinal stromal tumors (GIST) patients resistant to or intolerant of the standard treatment, Gleevec (imatinib mesylate), showed
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.